Carglumic acid (Ucedane®). HTA ID: 22035

Assessment Status Rapid Review complete
HTA ID 22035
Drug Carglumic acid
Brand Ucedane®
Indication Treatment of hyperammonaemia due to N-acetyl-glutamate synthase (NAGS) primary deficiency.
Assessment Process
Rapid review commissioned 16/05/2022
Rapid review completed 21/06/2022
Rapid review outcome A full HTA is not recommended. The NCPE recommends that carglumic acid (Ucedane®) not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.